Sonoma Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on September 15 and September 21, 2021. The filing covers corporate governance actions, including director elections, executive compensation votes, auditor ratification, and the adoption of an equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Proposal 1 (Director Election): Philippe Weigerstorfer was elected as Class I Director with 459,771 votes for and 89,996 withheld.
- Proposal 2 (Executive Compensation): Stockholders approved the advisory vote on executive compensation for the fiscal year ended March 31, 2021. Results: 326,511 For, 204,217 Against, 19,039 Abstain.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Frazier & Deeter LLC as the independent registered public accounting firm. Results: 1,162,699 For, 14,184 Against, 20,313 Abstain.
- Proposal 4 (Equity Incentive Plan): The adoption of the 2021 Equity Incentive Plan initially failed to reach the necessary votes on September 15. The meeting was adjourned to September 21, 2021. On the adjourned date, the proposal was approved with 273,042 For, 272,046 Against, and 18,807 Abstain.
Management Commentary and Corporate Changes
Sharon Barbari retired as a member of the Board of Directors and its committees effective upon the conclusion of the annual meeting. Following her retirement, the Board realigned committee structures:
- Audit Committee: Jerry McLaughlin (Chair), Philippe Weigerstorfer (Member).
- Compensation Committee: Jerry McLaughlin (Chair), Jay Birnbaum (Member).
- Nominating and Corporate Governance Committee: Jay Birnbaum (Chair), Philippe Weigerstorfer (Member).
Investor Verification Checklist
- Verify the final vote count for the 2021 Equity Incentive Plan, noting the narrow margin of approval (273,042 vs. 272,046) after the adjourned meeting.
- Confirm the updated composition of the Board of Directors and committee assignments following Sharon Barbari's retirement.
- Review the definitive proxy statement filed on July 29, 2021, for detailed descriptions of the executive compensation and equity plan terms.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.